The Short-term Effect of Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy

A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study

“…Three patients had complete resolution of SFF by month 3 (figure 2), while three others were dry by months 4–6. This rate of improvement may be similar to that reported for PDT and potentially more rapid than reported for ranibizumab 14. There was no strong correlation between change in choroidal thickness and change in SFF.…”

“…A recent meta-analysis of controlled trials using intravitreal bevacizumab failed to reveal a benefit in either BCVA or CMT 20. A randomised trial using ranibizumab likewise demonstrated a suboptimal response in chronic CSCR, and ranibizumab was found to be inferior to PDT in improving both anatomy and vision in chronic CSCR 14. To the best of our knowledge, this is the first investigation of intravitreal aflibercept injection as a treatment for chronic CSCR.…”

“…Case studies of intravitreal anti-VEGF medications in patients with persistent or chronic CSCR have found improvements in visual acuity, neurosensory detachment resolutions and improvements in RPE leaks on FA 14 15. However, prospective studies using anti-VEGF medications for CSCR have shown mixed results 16 17…”